In a second presentation of data from the same cohort of 58 evaluable patients, CD4 and CD8 positive T cells were activated with pooled E6 and E7 peptides and tested for interferon gamma production and degranulation. Blinded histologic sections of the final cervical conization specimens were independently graded for inflammation using a standardized protocol (0 no inflammation and 4 the highest level of inflammation.). There was significantly more cervical inflammation in patients who did not undergo regression after HspE7 immunotherapy. Local inflammation did not correlate with type-specific HPV infection or systemic T cell responses to HPV peptides; however, this study may have been underpowered to predict these observations in this subset of women with heterogeneous T cell responses. Further studies are currently underway.
About HspE7, Lead Product Candidate:
HspE7 is a novel therapeutic vaccine candidate for the treatment of diseases caused by the human papillomavirus (HPV), one of the most common sexually transmitted diseases in the world. HspE7 is derived from Nventa's proprietary CoVal(TM) fusion platform, which uses recombinant DNA technology to covalently fuse stress proteins to target antigens, thereby stimulating cellular immune system responses. Stress proteins, also known as heat shock proteins (Hsps), are naturally present in the human body and play important roles in the immune system, including transporting substances within cells and activating cells of the immune system. Nventa is pursuing clinical development of HspE7 in combination with an adjuvant.
About Nventa Corporation:
Nventa is developing innovative therapeutics for the treatment
of viral infections and cancer, with a focus on diseases caused by
the human papillomavirus (HPV). The corporation is publicly traded
on the Toronto Stock Excha